Wave Life Sciences, Inc. WVE
Set alert
3.59 USD -0.04 -1.10%
At close
3.83 +0.24 +6.69%
Pre-market · Nov 2, 4:59 AM ET
3.43 Day range 3.70
3.04 52-week range 21.73
- YTD
- -78.88%
- 1 year
- -56.75%
- Open
- 3.62
- Prev close
- 3.63
- Mkt cap
- 708.05M
- Vol
- 3.33M
- Avg vol
- 3.31M
- EPS
- -1.07
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.43
- High
- 3.70
- Forward P/E
- -4.33
- Beta
- -1.29
- Short ratio
- 5.75
- Inst. own
- 85.60%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 5.77
- 200-d avg
- 9.39
- 1y target
- 19.06
2Y chart
Events in this range
- Jul 30, 2025Earnings: -0.31; estimate -0.29; surprise -6.9%
- Nov 10, 2025Earnings: -0.32; estimate -0.3; surprise -6.67%
- Feb 26, 2026Earnings: -0.3; estimate -0.28; surprise -7.14%
- Apr 28, 2026Earnings: -0.13; estimate -0.34; surprise 61.76%
- May 19, 2026Rating: HC Wainwright & Co. · Buy → Buy
- May 20, 2026Rating: Wells Fargo · Overweight → Overweight
- Jul 30, 2026Earnings: -0.34; estimate -0.29975; surprise -13.43%
- Jul 31, 2026Rating: Wedbush · Outperform → Outperform
- Jul 31, 2026Rating: B. Riley Securities · Buy → Buy
- Jul 31, 2026Rating: Citigroup · Buy → Buy
- Aug 4, 2026Rating: Mizuho · Outperform → Outperform
Signals (96)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 19, 2026 | 1 week ago |
| RSI: Oversold | Oct 5, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| RSI: Oversold | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Aug 11, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 11, 2026 | 2 months ago |
| SMA: Bullish | Aug 6, 2026 | 2 months ago |
| SMA: Bearish | Aug 5, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 4, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 31, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 28, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 16, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 9, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 5, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 4, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 3, 2026 | 5 months ago |
| RSI: Oversold | Jun 2, 2026 | 5 months ago |
| MACD: Buy Signal | May 21, 2026 | 5 months ago |
| MACD: Sell Signal | May 20, 2026 | 5 months ago |
| RSI: Oversold | May 19, 2026 | 5 months ago |
| MACD: Buy Signal | Apr 14, 2026 | 6 months ago |
| RSI: Oversold | Apr 6, 2026 | 6 months ago |
| SMA: Bearish | Mar 26, 2026 | 7 months ago |
| RSI: Oversold | Mar 26, 2026 | 7 months ago |
| SMA: Bearish | Mar 12, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 12, 2026 | 7 months ago |
| SMA: Bullish | Mar 11, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 11, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 6, 2026 | 8 months ago |
| SMA: Bearish | Feb 27, 2026 | 8 months ago |
| SMA: Bullish | Feb 26, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 20, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 12, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 10, 2026 | 8 months ago |
| SMA: Bearish | Jan 28, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 30, 2025 | 10 months ago |
| SMA: Bullish | Dec 8, 2025 | 10 months ago |
| RSI: Overbought | Dec 8, 2025 | 10 months ago |
| SMA: Bullish | Dec 4, 2025 | 11 months ago |
| SMA: Bearish | Dec 1, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 25, 2025 | 11 months ago |
| SMA: Bullish | Nov 24, 2025 | 11 months ago |
| SMA: Bearish | Nov 10, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 10, 2025 | 11 months ago |
| SMA: Bearish | Nov 4, 2025 | 12 months ago |
| SMA: Bullish | Oct 30, 2025 | 1 year ago |
| SMA: Bullish | Oct 29, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 29, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 23, 2025 | 1 year ago |
| SMA: Bearish | Oct 16, 2025 | 1 year ago |
| SMA: Bullish | Oct 15, 2025 | 1 year ago |
| SMA: Bearish | Oct 10, 2025 | 1 year ago |
| SMA: Bullish | Oct 9, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 29, 2025 | 1 year ago |
| RSI: Oversold | Sep 24, 2025 | 1 year ago |
| RSI: Oversold | Sep 12, 2025 | 1 year ago |
| SMA: Bearish | Sep 3, 2025 | 1 year ago |
| SMA: Bearish | Sep 3, 2025 | 1 year ago |
| SMA: Bullish | Sep 2, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 2, 2025 | 1 year ago |
| SMA: Bearish | Aug 29, 2025 | 1 year ago |
| SMA: Bullish | Aug 22, 2025 | 1 year ago |
| RSI: Overbought | Aug 22, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 15, 2025 | 1 year ago |
| RSI: Overbought | Aug 15, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 7, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 1, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 31, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 7, 2025 | 1 year ago |
| SMA: Bullish | Jul 2, 2025 | 1 year ago |
| SMA: Bearish | Jun 27, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 27, 2025 | 1 year ago |
| SMA: Bullish | Jun 23, 2025 | 1 year ago |
| SMA: Bearish | Jun 20, 2025 | 1 year ago |
| SMA: Bullish | Jun 5, 2025 | 1 year ago |
| MACD: Buy Signal | May 29, 2025 | 1 year ago |
| MACD: Sell Signal | May 21, 2025 | 1 year ago |
| MACD: Buy Signal | May 19, 2025 | 1 year ago |
| MACD: Sell Signal | May 15, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 21, 2025 | 1 year ago |
| RSI: Oversold | Apr 3, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 27, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 26, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 25, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 24, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 21, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 12, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 7, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 4, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 3, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 28, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 25, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 19, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 10, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 24, 2025 | 1 year ago |
Key statistics
- Market cap
- 1.02B
- Enterprise value
- 583.55M
- Trailing P/E
- 0.00
- Forward P/E
- -4.33
- PEG ratio
- 0.00
- Price / sales
- 15.55
- Price / book
- 1.87
- EPS (TTM)
- -1.08
- Beta
- -1.29
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 65.37M
- Revenue growth
- -73.90%
- Free cash flow
- -128.78M
- Total cash
- 490.60M
- Total debt
- 43.59M
- Return on equity
- -67.42%
- Shares outstanding
- 197.05M
- Short % of float
- 10.14%
- 50-day average
- 5.77
- 200-day average
- 9.39
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 19.06 +431.0% upside
Now 3.59
- Target (low)
- 12.00
- Target (mean)
- 19.06
- Target (high)
- 42.00
Ratings (0m) 16 16 buy · 0 hold · 0 sell
- Strong buy2
- Buy14
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate -0.31703.
Financials — quick view
WVE Revenue — quarterly 13.16M
WVE Net income — quarterly -61.91M
WVE EPS — quarterly -0.30
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | -0.33 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | -0.29975 | -0.34 | -0.04 | -13.43% |
| Apr 28, 2026 | Mar 31, 2026 | -0.34 | -0.13 | +0.21 | +61.76% |
| Feb 26, 2026 | Dec 31, 2025 | -0.28 | -0.30 | -0.02 | -7.14% |
| Nov 10, 2025 | Sep 30, 2025 | -0.30 | -0.32 | -0.02 | -6.67% |
| Jul 30, 2025 | Jun 30, 2025 | -0.29 | -0.31 | -0.02 | -6.90% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 4, 2026 | Mizuho | main | Outperform | Outperform |
| Jul 31, 2026 | Citigroup | main | Buy | Buy |
| Jul 31, 2026 | B. Riley Securities | main | Buy | Buy |
| Jul 31, 2026 | Wedbush | main | Outperform | Outperform |
| May 20, 2026 | Wells Fargo | main | Overweight | Overweight |
| May 19, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Wave Life Sciences, Inc.
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- wavelifesciences.com
News
- Canaccord Genuity Maintains Buy on Wave Life Sciences, Raises Price Target to $44
- Oppenheimer Maintains Outperform on Wave Life Sciences, Lowers Price Target to $29
- Wave Life Sciences, Inc. (WVE) Q3 2026 Earnings Call Transcript
- WAVE Life Sciences Q3 Earnings Call Highlights
- Wave Life Sciences (WVE) Reports Q3 Loss, Tops Revenue Estimates
- Wave Life Sciences Anticipates $12M Milestone Payment From GSK In Q4
- WAVE Life Sciences Q3 EPS $(0.30) Beats $(0.33) Estimate, Sales $13.158M Beat $4.317M Estimate
- Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update
- WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path
- Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026
Your note
Sign in to keep a note on WVE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOLNO PAUL B. M.D. | Chief Executive Officer | Sale | Feb 8, 2026 | 275,520 |
| CORRIGAN MARK | Director | Sale | Dec 7, 2025 | 28,815 |
| FRANCIS CHRISTOPHER JOHN | Officer | Conversion of Exercise of derivative security | Feb 25, 2026 | 61,867 |
| GSK PLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 10, 2025 | 0 |
| MORAN KYLE | Chief Financial Officer | Sale | Feb 8, 2026 | 134,385 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Mar 29, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Kennedy Capital Management, LLC | 0.00% | 429,121 | 2.21M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 2.09% | 4,111,308 | 21.21M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.83% | 3,598,451 | 18.57M | Jun 29, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1.16% | 2,287,103 | 11.80M | Mar 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1.07% | 2,107,233 | 10.87M | Mar 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 0.84% | 1,659,857 | 8.56M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.82% | 1,610,961 | 8.31M | Mar 30, 2026 |